Research programme: virus-like particles - Agilvax

Drug Profile

Research programme: virus-like particles - Agilvax

Alternative Names: AX 03; AX 09; AX 14; Breast cancer immunotherapy - Agilvax; Dengue vaccine - Agilvax; Human papilloma virus vaccine - Agilvax; Malaria vaccine - Agilvax; Non-Hodgkin's lymphoma immunotherapy - Agilvax; Ovarian cancer immunotherapy - Agilvax; Pan-Ebola vaccine - Agilvax; Pan-Filovirus vaccine - Agilvax; Respiratory syncytial virus vaccine - Agilvax

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agilvax
  • Class Virus-like particle vaccines
  • Mechanism of Action CD44 antigen modulators; Immunogenetic stimulants; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Dengue; Human papillomavirus infections; Malaria; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory syncytial virus infections
  • Research Ebola virus infections; Viral haemorrhagic fevers

Most Recent Events

  • 05 Dec 2017 Agilvax plans a phase I trial for Breast cancer in USA
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 06 Sep 2016 Agilvax receives patent allowance for human papillomavirus vaccine candidate in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top